Slide 1: Cover letter to stock exchanges: Investor Presentation FY2021-22
LUPIN I... ~ May 19, 2022 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. v-N'ational Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. Dear Sir/Madam, Sub: Investor Presentation FY2021-22. Pursuant to R
Slide 2: Investor Presentation FY 2021-22
Investor Presentation FY 2021-22 19th May 2022
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Strategic Vision: A Global Pharma Company Focused on our Core Growth Platforms
Strategic Vision: A Global Pharma Company Focused on our Core Growth Platforms India Complex Gx Global Developed Gx Region Platforms market footprint Achieving substantially Substantial and scaled Operational efficiency above market growth product platforms from Global presence Organic and in-organi
Slide 5: Industry trends
Industry trends Price erosion has Global Need for low India growth FDA resumes become business Inflationary competition to remain world-wide site as usual for US Gx Head Winds launches strong inspections Pressure has increased Risk of high input prices Excellence in R&D more Growth likely to Pipelin
Slide 6: Lupin Today
Lupin Today Financial Metrics Globally Major Markets Market Cap (3) US$ 4.0 bn 10th 6th 3rd 6th Largest Generic Largest Indian Largest in India Pharma Revenue (FY22)(4) US$ 2.2 bn company Pharma the US Market Rank2 (by sales1) (by global sales1) (by prescriptions2) EBITDA (FY22)(4) US$ 311 mn Nether
Slide 7: Q4 FY2022 Snapshot
Q4 FY2022 Snapshot Sales (INR mn, YoY Growth) Important developments Commercial • Lupin Completes Acquisition of Brands from Anglo-French India, North • Completed Southern Cross acquisition in Australia 13,511 America, Total 14,162 • Lupin and Yabao Announce Strategic Partnership in China 38,645, 2.
Slide 8: Q4FY22 North America
Q4FY22 36.6% YoY QoQ North America % of Sales -5.3% -10.2% US Generics: An established leader1 Managing our transition to Complex Generics 44 22.6% 113 US quarterly sales ($ mn) Number of Albuterol Gx Number of 202 195 products Market share Products Top 3 184 181 Market leader by Market Share 172 3r
Slide 9: India Business Update
Q4FY22 35.0% YoY QoQ India Business Update % of Sales 5.0% -8.3% Q4 growth at 5% YoY; domestic formulations grew 13.3% YoY with contribution from key therapy areas India Quarterly Sales (INR mn) Lupin continues to outpace industry growth in Chronic 16,362 15,435 CAGR MAT Mar’18 – ’22 Lupin Rank1 14,
Slide 10: Other Markets
Other Markets • Germany: EUR 8.4 mn sales in Q4 FY22 EU5 Developed • Tempil ® & Mens Health Portfolio have contributed to double-digit YoY growth • 4th largest generics player1 Australia • Growth of 30% against industry growth of 7.5%1 • 4th largest Rx generics player2; Market leader in CVS space So
Slide 11: P&L Highlights- Q4 FY 2022
P&L Highlights- Q4 FY 2022 % of % of QoQ % of YoY Amount in INR mn Q4FY22 Q3FY22 Q4FY21 Sales Sales Growth Sales Growth Sales 38,645 100.0% 40,875 100.0% -5.5% 37,593 100.0% 2.8% Other operating income 185 0.5% 734 1.8% -74.8% 238 0.6% -22.3% Total revenue 38,830 100.5% 41,609 101.8% -6.7% 37,831 10
Slide 12: P&L Highlights - FY22
P&L Highlights - FY22 YoY Amount in INR mn FY2022 % of Sales FY2021 % of Sales Growth Sales 161,928 100.0% 149,270 100.0% 8.5% Other operating income 2,127 1.3% 2,360 1.6% -9.9% Total revenue 164,055 101.3% 151,630 101.6% 8.2% Gross Profit 97,116 60.0% 95,648 64.1% 1.5% (excl. other operating income
Slide 13: Key Financial Metrics
Key Financial Metrics R&D (INR mn) Capex (INR mn) 3,737 2,787 3,546 3,427 3,442 1,451 1,577 3,300 1,396 1,057 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 R&D (% of Sales) Net debt/ Equity 0.18 9.1% 0.16 8.8% 8.9% 8.7% 8.2% 0.05 (0.02) (0.01) Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY
Slide 14: Complex Generics and Biosimilars Opportunity
Complex Generics and Biosimilars Opportunity Opportunities exist in products with barriers to entry Generics market offers opportunities in With several biologics going off-patent, biosimilars • First to market / first to file opportunities have a long way to go with new launches and • Complex dosag
Slide 15: Complex Generics and Biosimilars Opportunity
Complex Generics and Biosimilars Opportunity R&D investments focused toward complex generics and biosimilars • Products in development target US$ 70.7 bn of which complex categories account for ~85% • Launches in key categories like Inhalation and biosimilars • Several filings in each of the key cat
Slide 16: Evolving our Generic Portfolio and Pipeline
Evolving our Generic Portfolio and Pipeline by timing of material contribution Injectables Robust suite of depot, liposomal, peptide and iron injectable products in development Inhalation Scaling our early yet Women’s meaningful launches while Health advancing our robust pipeline Evolving internal L
Slide 17: Progress on US Inhalation Pipeline
Progress on US Inhalation Pipeline Product (Market Size1) Formulation PK Study PD Study Filing Launched Albuterol MDI Launched in US Brovana AG Launched in US Tiotropium DPI Tiotropium DPI is filed and under review MDI 1 MDI 1 is filed MDI 2 PK Studies to commence shortly MDI 3 PK Studies to commenc
Slide 18: Progress on US Injectables Pipeline
Progress on US Injectables Pipeline Nanomi Pipeline Product Formulation Clinical Phase Filing (Market Size)1 Risperdal Consta • Risperidone is at end of clinical phase Depot 2 • Depot 2 and Depot 3 are at end of formulation development stage Depot 3 LRP Complex injectables Pipeline Product Name API/
Slide 19: Progress on Biosimilar Pipeline
Progress on Biosimilar Pipeline Reference Clone & Process Pre- Filing in US/EU/JP Approval Molecule Phase I Phase III Product Development Clinical US/EU/JP & Launch Launched in JP/EU/India/Thailand Etanercept Enbrel® Filed: Canada/Australia and several other Emerging Markets Neulasta® (PFS & US BLA
Slide 20: Improvement initiatives
Improvement initiatives Optimization plan Key initiatives Idle Plant Work Force Network Time Optimization Optimization Write-offs Returns Optimizing R&D investment Air FTS Integrated Business Planning Freight Low Margin SKUs 19
Slide 21: Optimizing R&D investment
Optimizing R&D investment Invested INR 14 bn or 8.7% of sales on R&D in FY22at 7 R&D sites globally R&D spend Generics filings Pipeline R&D Cost (INR bn) R&D as % of Sales 25.0 13.5% 14% 457 cumulative filings 11.9% 20.0 10.5% 10.3% 12% 9.6% 8.7% 10% 15.0 160 pending 8% 23.1 approval 10.0 18.5 6% 15
Slide 22: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta ranks among 50 Most Powerful Women in Business - by Fortune India • Vinita Gupta, named among India’s 20 Most Influential Women in Healthcare by BW Healthcare World • Lupin wins two awards at the prestigious India Pharma Awards 2021 • “BEST Award” from Ass
Slide 23: THANK YOU
THANK YOU Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai 400 055, India. Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com lupin LupinGlobal LupinWorld Lupin Global